Save 35% + Free Shipping — Single Vials In Stock · code

Back to Catalog

Peptides

SS-31 10 mg

$119Per Unit

Synthetic water-soluble tetrapeptide that selectively concentrates in the inner mitochondrial membrane and associates with cardiolipin to optimize cristae structure.

Lot SS312026-10J · COA on request
Lyophilized tetrapeptide, sterile vial, 10 mg fill
2–8°C

5 × $119.00 = $595.00 $386.75 (35% off with code EHAB35 + free shipping)

Your order of 5 units qualifies: apply code EHAB35 at checkout for 35% off and free shipping.

SS-31 10 mg

$386.75 for 5 · 35% off

Research use only
SS-31 10 mg research packaging
Lyophilized tetrapeptide, sterile vial, 10 mg fill
Anubis Research Labs

Documentation

The certificate of analysis for the current lot (Lot SS312026-10J) is sent on request, so you can review identity and purity testing before you order.

Request the lot COA

Research summary

SS-31 (elamipretide)(Elamipretide, Bendavia)

Regulatory status
Accelerated FDA approval (Forzinity, Sep 2025) to improve muscle strength in Barth syndrome; other indications remain investigational.
Strongest evidence
Approved for one rare disease; mixed results elsewhere
Overview

Elamipretide is a mitochondria-targeted tetrapeptide that binds cardiolipin in the inner mitochondrial membrane.

What researchers study it for
  • Barth syndrome
  • Primary mitochondrial myopathy
  • Dry age-related macular degeneration (phase 3)
Mechanism

Binds cardiolipin, a lipid essential to the structure of the mitochondrial energy machinery.

Evidence (3)
  1. Approved drug

    First approval (Drugs, 2026)

    Granted U.S. accelerated approval in September 2025 for Barth syndrome patients weighing at least 30 kg - the first disease-specific Barth treatment.[1][2]

  2. Human · small / uncontrolled

    TAZPOWER extension (Genet Med 2024)

    Open-label extension in 10 Barth patients (8 reached week 168): improvements in walking distance and fatigue scores, with injection-site reactions most common.[3]

  3. Human · randomized trial

    MMPOWER-3 (Neurology 2023)

    218 adults with primary mitochondrial myopathy. The trial did not meet its primary endpoints.[4]

Limitations of the evidence
  • Approval is for one ultra-rare disease and is accelerated (confirmatory evidence required).
  • Products on this site are sold for laboratory research only. They are not the medicines used in the trials above, and those results do not apply to research material.
Sources (4)
  1. 1.Elamipretide: First ApprovalShirley M. Drugs. 2026 Review
  2. 2.Forzinity (elamipretide) - approval 2025-09-19Drugs@FDA, NDA 215244 Approved drug
  3. 3.Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWERThompson WR et al. Genet Med. 2024 Human · small / uncontrolled
  4. 4.Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical TrialKaraa A et al. Neurology. 2023 Human · randomized trial
Every published studyPubMed search: elamipretide OR SS-31(opens in a new tab)Every registered trialClinicalTrials.gov search: elamipretide OR SS-31(opens in a new tab)

Reviewed 2026-10-02. Summaries describe published research and regulatory records; they are not medical advice and do not describe how to use this product. Sold for laboratory research use only.